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A B S T R A C T
Background: Tobacco dependence remains the leading preventable cause of death in the developed world.
Smokers are disproportionately from lower socioeconomic groups, and may use the hospital emergency de-
partment (ED) as an important source of care. A recent clinical trial demonstrated the efficacy of a multi-
component intervention to help smokers quit, but the independent contributions of those components is un-
known.
Methods: This is a full-factorial (16-arm) randomized trial in a busy hospital ED of 4 tobacco dependence in-
terventions: brief motivational interviewing, nicotine replacement therapy, referral to a telephone quitline, and a
texting program. The trial utilizes the Multiphase Optimization Strategy (MOST) and a novel mixed methods
analytic design to assess clinical efficacy, cost effectiveness, and qualitative participant feedback. The primary
endpoint is tobacco abstinence at 3 months, verified by participants' exhaled carbon monoxide.
Results: Study enrollment began in February 2017. As of April 2017, 52 of 1056 planned participants (4.9%)
were enrolled. Telephone-based semi-structured participant interviews and in-person biochemical verification of
smoking abstinence are completed at the 3-month follow-up. Efficacy and cost effectiveness analyses will be
conducted after follow-up is completed.
Discussion: The goal of this study is to identify a clinically efficacious, cost-effective intervention package for the
initial treatment of tobacco dependence in ED patients. The efficacy of this combination can then be tested in a
subsequent confirmatory trial. Our approach incorporates qualitative feedback from study participants in
evaluating which intervention components will be tested in the future trial.
Trial registration: Trial (NCT02896400) registered in ClinicalTrials.gov on September 6, 2016.
1. Introduction
Fifty years after the landmark 1964 Surgeon General's report,
smoking remains the leading cause of preventable death in the United
States, with about 480,000 deaths per year [1]. In 2012, $289 billion in
direct and indirect costs were associated with tobacco use. In 2015,
15.1% of Americans smoked [2], still far short of the Healthy People
2020 goal of 12% prevalence [3]. Certainly, significant progress has
been made, with the prevalence of smoking among U.S. adults reduced
from 42% in 1964. However, after half a century of research,
regulation, policy advances, drug development, public service cam-
paigns, and litigation, significant challenges in treating tobacco remain.
Smoking is an addiction that has become increasingly disproportionate
among the medically disadvantaged: those with low income or low
education, the mentally ill, and individuals with other substance use
disorders. These are among the groups identified in a 2006 NIH State-
of-the-Science conference as those most in need of advances in treat-
ment and treatment engagement [4].
These groups of smokers are commonly treated in hospital emer-
gency departments (EDs). EDs are a frequent site of care for all
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Americans, with approximately 136 million visits across 4000 EDs in
2011 [5]. ED patients are disproportionately of low socioeconomic
status, more likely to smoke compared with the general population,
[6,7] and more likely to have limited or irregular access to primary
care. ED smokers often present with illnesses caused or exacerbated by
tobacco use or have injuries (e.g., lacerations, fractures) for which
smoking impedes their healing [8–10]. Hence the ED visit represents an
opportune time to discuss patients' tobacco use, its relevance to their
current visit, and to initiate tobacco treatment and aftercare [11]. This
represents an evolving standard of treatment in the ED care of the pa-
tient who smokes [12].
Our group has recently demonstrated the efficacy of a multi-
component intervention that includes behavioral and pharmacologic
therapies in promoting tobacco abstinence among ED smokers [10]. In
a randomized trial of 778 smokers, a combination of brief motivational
interviewing, six weeks of nicotine patches and gum, referral to a
smokers' quitline, and a follow-up phone call resulted in a significant
improvement in the three-month, biochemically confirmed abstinence
rate: 12.2% vs. 4.9% [10]. Our model adapts the treatment paradigm
known as Screening, Brief Intervention, and Referral to Treatment
(SBIRT) [13]. The components of our intervention were: a brief adap-
tation of motivational interviewing (MI), called the Brief Negotiation
Interview [14], initiation of nicotine replacement therapy (NRT) in the
ED with provision of a 6-week supply of patches and gum, referral to
the Connecticut State smokers' telephone quitline (QL), provision of a
smoking cessation brochure, and the provision of a booster phone call
3 days after enrollment [10]. Recent pilot studies conducted by our
group showed the feasibility and potential efficacy of ED-initiated
short-message-service (SMS) for tobacco dependence treatment
[15,16].
One limitation of our work is that we cannot disentangle the con-
tribution to abstinence of the individual components of the interven-
tion. We assume that each is important, but we cannot model their
contributions, or whether important interactions exist. It is therefore
imperative to identify the most clinically effective and cost-effective
components to create an efficacious intervention that can be delivered
for the lowest cost possible in real-world ED settings.
1.1. Trial objectives
The goal of this study is to identify components of an ED-based
intervention which are optimally effective for treating adult smokers.
2. Methods
2.1. Overview and study design
The MOST design, developed by Collins and outlined in Fig. 1, is an
iterative process that often employs a factorial design (Optimization)
followed by a traditional randomized clinical trial (Evaluation), that
allows investigators to efficiently identify efficacious components of an
intervention, subject to a cost constraint [17–21]. Intervention com-
ponents may be studied in a full- or reduced-factorial design. MOST has
been used to design interventions to treat tobacco dependence [21,22],
but, to our knowledge, has not been previously used in the ED setting.
Our group's work in ED-initiated tobacco dependence treatment
conducted to date would constitute the Preparation phase. MOST has
been used in a number of smoking cessation trials [22–25], but not in
the ED. MOST borrows 2 principles from engineering: (1) the resource
management principle, which says that research resources should be
managed strategically to maximize information gain in a timely
fashion, and (2) continuous optimization, which says that a new cycle
of research should begin soon after conclusion of the previous cycle,
employing the information gained from that cycle [25].
Our study will use a full 2 [4] (i.e. 16-arm) factorial design to
evaluate the effects of 4 intervention components at a fraction of the
cost, using one-fourth of the participants it would take to conduct 4
individual experiments to evaluate each component separately. Table 1
outlines the 16 arms.
In addition, qualitative participant interviews will provide a
nuanced understanding of how patients' perceptions about using the
various components and contextual factors may influence the feasibility
of implementation. These perceptions and contextual factors may not
otherwise be captured by traditional survey methods, and are therefore
included in our mixed methods approach to improve the readiness of
the final treatment package for real-world implementation. A sub-
sequent traditional randomized trial is planned as a future study, which
will require additional external support.
Our multicomponent intervention consists of the following: (1) a
Brief Negotiation Interview (our brief adaptation of motivational in-
terviewing [26]), delivered by a trained staff member; (2) provision of
6 weeks of nicotine patches and gum to the research participant, with
application of the first patch in the ED; (3) active referral to the Con-
necticut Smokers' Quitline; and (4) enrollment in the SmokefreeTXT
short-messaging service (SMS) texting program for mobile phones. All
patients will receive the smoking cessation brochure. Using MOST
principles, the screening phase will use a 2 × 2× 2× 2 full-factorial
design to identify the components most likely to be efficacious in
Fig. 1. Multiphase Optimization Strategy (MOST).
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combination. Although the factorial design requires the allocation of
participants to 16 different combinations of the 4 components
(Table 1), evaluation of each individual component is performed
comparing all of those receiving a component to all of those not re-
ceiving a component, making this an efficient design. For instance,
evaluation of the BNI component will compare those randomized to
conditions 1 through 8 to those in conditions 9 to 16. Based on the
results of the screening phase in conjunction with findings from the
qualitative analysis, we will design and propose a 2-arm randomized
clinical trial comparing the efficacy of the multicomponent intervention
package to usual care for the confirmatory phase.
2.2. Participants
2.2.1. Inclusion criteria
Patients who present to the adult ED at Yale-New Haven Hospital
(YNHH) are eligible for the study if they are: (1) 18 years or older (2)
have smoked at least 100 cigarettes in their lifetime (3) describe
themselves as every-day or some-day smokers (4) smoke at least 5 ci-
garettes/day, on average (5) own a cellphone with texting capability,
and (6) are able to give written informed consent.
2.2.2. Exclusion criteria
Patients are excluded for: (1) not being able to read or understand
English; (2) currently receiving formal tobacco dependence treatment;
(3) having a life-threatening or unstable medical, surgical, or psychia-
tric condition; (4) being unable to provide at least one collateral con-
tact; (5) living out-of-state; (6) planning to leave the ED against medical
advice (7) being pregnant (self-report or urine testing) or currently
nursing or trying to conceive.
2.3. Setting
YNNH is part of an academic medical center that serves a moder-
ately poor city in the northeastern United States; in 2015, 26.6% of New
Haven's 130,000 residents lived in poverty [27]. In 2013, women re-
presented approximately 55% of the ED population; the mean age of ED
adults was 41 years. The racial mix of our patients reflects that of New
Haven: 65% White, not Hispanic; 23% African-American, not Hispanic,
10% Hispanic; 2% other. Payor status for ED smokers is approximately
55% Medicaid, 5% Medicare, 30% private insurance, and 10% self-pay.
The Adult ED is a level one trauma center that treats 92,000 adult visits
per year. The prevalence of smoking in the city is 18%, slightly above
the national average [28].
2.4. Screening procedures and recruitment
Participants are being recruited during all days of the week from
8 am-10 pm. Potential participants will meet with a research assistant
to be evaluated for eligibility. Patients are asked for verbal consent to
complete the 2-item tobacco screener used by the Behavioral Risk
Factor Surveillance System (Do you smoke cigarettes every day, some
days, or not at all? Have you smoked at least 100 cigarettes in your
entire life?). Patients who report smoking but are not eligible are given
a handout recommending that they abstain from smoking, contact their
primary care provider, and consider calling the quitline. Individuals
who meet inclusion and exclusion criteria and consent to participate
have baseline assessments performed and are then randomized to one of
16 combinations of components (Table 1).
2.5. Randomization
To assure equal intervention allocation and concealment of inter-
vention allocation a random permuted block sequence was generated
(via www.randomization.com) and intervention assignments dis-
tributed through the clinical trial data management system.
2.6. Interventions
Our previous work employed a multicomponent approach to ED-
initiated tobacco treatment, which used both pharmacologic and be-
havioral approaches. All components are evidence-based; most are cited
in the 2008 Public Health Service clinical practice guideline [29]. The
newest approach, text messaging on mobile phones, is supported by a
Cochrane review [30]. Below we discuss these components, the ratio-
nale for each, and supportive evidence. Our intent is to use the MOST
approach to identify the individual contributions of these components
and to assemble them into an intervention that is effective, efficient,
and scalable.
2.6.1. Brief Negotiation Interview (BNI)
Brief Negotiation Intervention (BNI) is a manual-guided brief in-
tervention that is an adaptation of motivational interviewing and has
been shown to be feasible and efficacious in the ED setting. The BNI
manual for this study is based on one that we used in our previous trial.
The purpose of the BNI is to assist patients in recognizing the proble-
matic nature of and changing their tobacco use. The main goals of the
interview are to elicit disincentives for smoking and compelling per-
sonal reasons/motives for quitting from the patient, thereby motivating
them to change their smoking behavior by reducing the number of ci-
garettes smoked daily or abstaining completely. The 4 steps of the BNI
are: 1) Raising the subject, 2) Providing feedback, 3) Enhancing moti-
vation and 4) Negotiating a plan.
The BNI is delivered and audiotaped by trained RAs who have a
bachelor's-level education. Tapes are reviewed biweekly by the RAs and
a clinical psychologist to assess fidelity to the scripted BNI protocol. In
our prior work, the BNIs average 10–15 min in length. RAs received
10 h of training in our manualized BNI. The training included role-play
of patient scenarios, followed by 1 week of shadowing an experienced
RA performing BNIs on ED patients. These procedures were used suc-
cessfully in our prior study [10].
If, during the BNI or other interactions, the participant discloses to
the RA risky behaviors such as suicidality, intimate partner violence, or
Table 1
Arms of the trial.

















Green = component is offered.
Red = component is not.
BNI = Brief negotiated interview.
NRT = Nicotine replacement therapy.
QL = Quitline referral.
Text = Smoke-free text.
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use of other substances, the RA notifies the treating ED physician.
2.6.2. Nicotine gum and patch, with initial dose in the ED
Participants randomized to NRT receive 6 weeks of patches (42
count) and gum (300 pieces of 2 mg). NRT dosing is tailored to the
participant's cigarette consumption (5–10 cigarettes/day: 14 mg patch
and 2 mg gum;> 10 cigarettes/day: 21 mg patch and 2 mg gum).
Patches come in 14 and 21 mg doses. The first patch is applied by an ED
nurse at the index visit. The RA then conducts a brief educational ses-
sion with the participant on the use of both the patch and the gum. This
approach, which employs immediate cessation of tobacco, stands in
contrast to the traditional model of setting a quit date several weeks
after the initiation of tobacco dependence treatment. In our previous
investigation, this approach was accepted enthusiastically by study
participants. Combination NRT is provided because it is generally more
efficacious than NRT monotherapy in promoting tobacco abstinence
[29].
2.6.3. Text messaging
We are using the SmokefreeTXT program, developed by the
National Cancer Institute of the NIH and available through Smokefree.
gov. SmokefreeTXT is a text messaging service designed for U.S. adults
who are trying to quit smoking. The program provides 24/7 en-
couragement, advice, and tips to help smokers quit, and stay quit.
Messages are timed around the quit date, and the program lasts
6–8 weeks depending on chosen quit date. Users receive 1–5 messages
per day and can receive additional quit support by texting one of
SmokefreeTXT's keywords.
The SmokefreeTXT library contains about 130 messages. In the
previous pilot study, a modest number of modifications were made and
primarily concerned time considerations (e.g., deletion of all messages
concerning the 2-week lead-in to the actual quit date) and tailoring
information to local resources for Connecticut residents. SmokeFreeTXT
employs a number of behavior change strategies, including feedback
and monitoring, social support, and shaping knowledge [31]. Based on
the qualitative data we collected during our pilot study [16], we offer
participants in the current trial a choice of how many messages they
receive per day (up to 2 messages or up to 4 messages per day) and the
time of day they receive the first message. We also added 18 messages
for participants presenting to the ED with specific chief complaints
(cardiac, respiratory, or wound care) during the index visit.
2.6.4. Active quitline referral
Participant information is faxed to the Connecticut QL's service
provider, Alere Wellbeing. QL staff then makes outbound calls to reach
participants, provide information about services standardly offered by
the Connecticut QL, and enroll interested participants in QL services.
The Connecticut QL currently offers residents the option of enrolling in
a one call, multiple call, or web-based tobacco cessation program. All
enrollees in the multiple call or web-based programs who meet medical
screening criteria are also eligible for two weeks of the nicotine patch,
gum or lozenge mailed from the QL. The call programs combine in-
dividualized telephone counseling, text messaging, mailed or online
materials, and an interactive online program to complement the phone-
based program. After the initial assessment and planning call, partici-
pants in the multiple call program receive 4 additional proactive
counseling calls. Calls are designed to help participants set a quit date,
design a plan for cessation, develop problem-solving and coping skills,
secure social support, and effectively use cessation medications, such as
NRT. Quit coaches are required to have a bachelor's degree, complete
over 200 h of education and training in tobacco cessation treatment,
and receive ongoing supervision. Calls are scheduled at convenient
times and at relapse-sensitive intervals; calls in the multiple call pro-
gram are typically completed within 2–3 months of program registra-
tion. Participants can also call for additional support between proactive
calls. The Alere program is based on the 2008 Public Health Service
clinical practice guideline [29] and grounded in Social Cognitive
Theory [32]. Its effectiveness has been validated by 3 randomized trials
[33–35], and several real-world evaluations [36–38]. In our prior
study, 32% of participants in the intervention arm engaged in ≥1 call
with the quitline [39].
Lastly, all participants are provided with a brochure that reviews
the health hazards of smoking, and provides the phone number for the
state quitline. In Connecticut, this brochure is produced by the State
Department of Public Health, printed in English and Spanish, and is
available in bulk at low cost. We believe that distributing this brochure
to all study participants is reasonable and ethical. Because provision of
the brochure is not manipulated in the experiment we will be unable to
isolate any discrete effect of the brochure on tobacco abstinence.
2.7. Primary outcome measure
The primary efficacy endpoint is biochemically verified 7-day ces-
sation at 3 months [40]. Tobacco cessation will be assessed by self-re-
port and confirmatory biochemical testing with exhaled carbon mon-
oxide. Patients who assert abstinence by phone interview will be asked
to return to the hospital for biochemical assessment of exhaled carbon
monoxide.
2.8. Secondary outcome measures
Secondary outcomes include use of cessation medications and ser-
vices, including use of the quitline, use of NRT, and use of other
pharmacotherapies such as bupropion and varenicline, as well as
changes in daily cigarette consumption. These will be assessed by self-
report and fax reports from the CT quitline. A brief, structured inter-
view called the Treatment Service Review (TSR) [41] will be ad-
ministered to collect information on the type and amount of services
received by participants, including ED visits, hospitalizations, primary
medical care visits, quitline utilization, and self-help sources of support
(e.g. web services). The TSR will be supplemented with questions on the
use of smoking cessation medications.
2.9. Analytic strategy
2.9.1. Overview
Intervention components will be analyzed over 3 domains, as out-
lined in Fig. 2. First, components will be assessed for clinical efficacy,
using traditional measures such as biochemically verified tobacco ab-
stinence. If clinically effective, components will then be analyzed for
cost-effectiveness and feasibility/acceptability to participants.
2.10. Assessing clinical efficacy
Participants will be contacted by telephone at 1 and 3 months after
enrollment. At 3 months, participants self-reporting tobacco abstinence
will be asked to return to the hospital to measure exhaled carbon
monoxide (CO). Participants whose breath CO levels are 9 ppm or less
will be considered abstinent [40].
Multivariable logistic regression will be used to model the primary
outcome, abstinence at 3 months. Per convention, in the primary ana-
lysis missing abstinence data, including absence of biochemical ver-
ification, will be coded as smoking. For this full-factorial design, the
model will include main effects for each of the 4 components as well as
all 2, 3 and 4-way interactions. The regression will also include baseline
covariates: age, sex, race/ethnicity, and smoking characteristics, such
as daily cigarette consumption. Main effects will be evaluated at the
0.05 significance level. Differences in proportions for the presence and
absence of each component (i.e. main effects) will be estimated along
with 95% confidence intervals using the bootstrap method [42]. A p-
value of 0.10 will be used as a guide to flag potentially important in-
teractions which will be explored graphically with a particular
S.L. Bernstein et al. Contemporary Clinical Trials 66 (2018) 1–8
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emphasis on identifying substantial synergistic effects or qualitative
(i.e. where the impact of 1 component changes direction depending on
the presence or absence of another component) effect modification.
Similar analyses will be performed at 1-month follow-up. Additionally,
a logistic regression with parameters estimated by weighted General-
ized Estimating Equations (GEE) will incorporate both 1- and 3-month
outcome data without imputing non-responders as relapse [43]. This
analysis weights for the probability of response and is valid under the
assumption that missing data are missing at random. Secondary out-
comes at 1 and 3 months will also be evaluated by a generalized linear
model with weighted GEE.
2.11. Justification of sample size
The goal of this proposal is to identify individual tobacco depen-
dence treatment intervention components which show clinical efficacy,
subject to constraints of cost effectiveness and acceptability. As each
component is allocated to half the participants, the sample size to detect
main effects in a full factorial MOST design depends not on the number
of components evaluated, but rather the smallest clinically important
difference between the presence and absence of a component. In our
previous trial, we found a difference of 7.3% in biochemically con-
firmed abstinence between the control and intervention arms at
3 months. It is reasonable to expect that, in this factorial trial, the effect
of individual components will be less than that seen in the multi-
component trial [17,44]. Therefore, we have chosen an absolute dif-
ference of 5% for the main effects of each component. (We considered a
narrower difference of 4%, but the sample size and resources needed
become unfeasible.) With a two-sided 0.05 significance level, and an
average abstinence proportion of 4.9% in the absence of a component, a
total sample size of 860 participants will provide 80% power to detect a
5% increase in the abstinence rate. We will enroll 1056 participants to
account for a 15% dropout rate by 3 months. We will investigate
whether the effect of a component is dependent on the levels of other
components (i.e. interactions), but our trial is not powered with the
intent to detect these interactions.
2.12. Assessing cost effectiveness
2.12.1. Overview
We will perform a series of incremental cost effectiveness analyses
(CEA) to determine whether the benefits of each component appear to
be worth the added costs, partially accounting for the interactive effects
of the components. Two outcomes will be considered: (1) number of
abstinent smokers at 3 months (measured by biochemically verified 7-
day tobacco abstinence) and (2) the cost per QALY saved. Following
CEA recommendations [45,46], baseline analyses will adopt a societal
perspective, considering all economic costs regardless of source. We
also will calculate incremental cost effectiveness ratios (ICERs) from the
payer's perspective, excluding patient costs and, in sensitivity analysis,
QL costs. We will use ICERs for other cessation interventions to select
an acceptable maximum cost/quality-adjusted life year (QALY) saved
for the tested program elements since we want to identify an ED ces-
sation approach that is at least as cost-effective as approaches based in
other settings [47–49].
2.12.2. Treatment costs
We will include costs of all smoking cessation treatment received by
participants, broken down by component (Table 2). Resource costs in-
clude costs of administering the BNI and medication (a purchased
item), administering the texting, and making the QL referral (i.e., IT
costs, cost of clinician time to administer the intervention, medication
delivered in hospital, incremental cost of longer follow-up booster
phone call), costs related to QL use, outpatient treatment costs, other
medical costs, and patient costs (e.g., time, transportation). In evalu-
ating a prior trial, we measured RA time for an ED-based BNI session.
Clinician time costs will include wages, fringe benefits, and overhead.
Cost of patient time will be calculated using the average wage rate in
the geographic area. Relevant medication use will be obtained from the
medical record; cost of medication will be based on the average of the
current formulary price for the top 5 health insurers in Connecticut.
Quitline costs: We will get the number of counseling calls completed
directly from QL records, then calculate costs of counselor and patient
time related to the calls (both scheduled QL calls and participant-in-
itiated calls). We will collect patient time on the website at 1 and
3 month assessments, as well as costs of any NRT shipped, and regis-
tration costs for quitline-managed web or texting services. We will ex-
clude research costs because these would not be incurred if our inter-
vention were standard care. Training and texting program setup costs
will be excluded from the main analyses. Although these startup costs
may be incurred, when distributed across many patients over many
years, they would be negligible. We will collect information on training
and setup costs and include in publications/sensitivity analysis, as these
may be of interest to decision makers.
2.12.3. Measuring effectiveness
We will assess effectiveness (i.e., abstinence) biochemically at
3 months. With the MOST design, regression will estimate quit rates for
the 4 potential intervention components, as well as the gains and losses
that occur when combining them. Over time, abstinence reduces
medical care utilization and improves quality of life. We will not track
those savings in our patient cohort. Instead, we will update our adap-
tation of a popular model that simulates them [50].
2.12.4. Calculating cost effectiveness ratios
We will calculate incremental cost effectiveness ratios (ICERs) in 2
passes. A naive first pass will array cost and regression-adjusted quit
rate for each of the 16 MOST cells, ignoring if differences are statisti-
cally significant. This naive look will let us drop clearly dominated cells
where higher cost is associated with a lower quit rate, as well as any
cells that proved infeasible in the clinical setting. In a refined pass, we
will define incremental component cost effectiveness as ΔC/ΔE, where
ΔC is the cost a component adds and ΔE is the effectiveness associated
with the component. This refined look at the remaining candidates will
use 2 effectiveness measures, the 3-month quit rate and the simulated
quality-adjusted life year (QALY) gain. A QALY is a standard measure of
health-related quality of life, defined so that a year in perfect health is
valued at 1.0 and death is valued at 0.0 [46]. Even if 1 component costs
more per quitter than another, it still may be worthwhile if it helps
more smokers to quit at an acceptable cost per QALY gained. By esti-
mating QALYs gained per quitter, we get a measure that lets us judge
Fig. 2. Schematic view of analytic strategy after factorial
trial.
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the cost of cessation gains relative to other smoking interventions, with
a tentative ceiling of $5000 per QALY gained that we will refine in year
4 by updating our literature review on cessation interventions regularly
used in medical settings.
The analysis will require estimates of the QALY losses and medical
costs averted by smoking cessation. For QALY loss, the most recent
estimates [51–53] are better than older estimates [54,55]. For medical
costs, we expect to use the latest update to CDC's SAMMEC model [1]
which builds from the methods pioneered by V. Miller [56]. We will
inflate all cost savings to the same year's dollars as the program costs
and compute present value of savings in future years at a 3% discount
rate. To account for relapse, we will insert our chosen smoking costs
and our observed quit rate pattern into the widely used BENESCO
(benefits of smoking cessation on outcomes) Markov simulation model
of cessation duration or a closely related model [47,48]. These models
stem from a 2002 World Health Organization model. The resulting es-
timates will let us answer the question of which efficacious ED-based
interventions maximize quits while staying below the acceptable cost
per QALY gained.
To better inform our package choice, we will estimate 95% CIs
around the ICERs. To estimate ratio variance, we will start with roughly
estimated standard errors or distributional data for each number in the
cost-effectiveness equation. We will use bootstrapping simulation
methods that form an empirical probability distribution [57]. To handle
estimates with unknown variance, notably the discount rate, we will
conduct sensitivity analyses. The sensitivity analyses examine if dif-
ferent input assumptions would change package selection.
2.13. Assessing feasibility, acceptability
A novel feature of this study is the prespecified use of qualitative
methods to assess the intervention. The goal of this analysis is to ensure
that intervention components are considered feasible, practical, and
acceptable by the patients who may use the package in real-world
settings.
Similar to our approach in the pilot study, we will conduct phone-
based, semi-structured interviews with a sub-sample of participants at
the 3-month follow-up assessment. The interview will begin with a set
of items that use a Likert format to obtain an overall rating of each
component that participants received, both alone and in combination.
We will use a purposive sampling strategy that will recruit equal
numbers of participants from each component (i.e., either as a single
component or in combination) to allow us to explore potential inter-
actions of components. Consent for the qualitative component will have
already been given at study enrollment. The semi-structured interviews
will be audio-recorded and subsequently transcribed and analyzed
thematically, Recruitment will continue until thematic saturation has
been achieved.
Components scoring well in Likert assessments and found feasible
and acceptable in interviews with participants (that are also clinically
efficacious and cost-effective) will be retained to study in the future
randomized trial.
The semi-structured interviews will be audio-recorded and subse-
quently transcribed, coded by study personnel with experience in
coding, and analyzed thematically in an ongoing and iterative process
[58,59] using qualitative analysis software ATLAS.ti (version 7.0; AT-
LAS.ti GmbH). Recruitment will continue until thematic saturation has
been achieved. We anticipate interviewing 80–100 participants.
3. Results
As of 12 July 2017, 203 participants have enrolled in the trial. Their
median age is 44 years (SD 12.6); 101 (50%) are male; their racial and
ethnic composition is 97 (48%) white, 70 (34%) African American, and 36
(18%) other. Thirty-three (16%) participants identify as Hispanic. Their
insurance coverage is 127 (63%) Medicaid, 6 (3%) Medicare, 20 (10%)
Medicaid and Medicare, 47 (23%) private insurance, and 3 (1%) unin-
sured. Recruitment is proceeding on schedule. One-month and three-
month follow-ups have begun, including the qualitative interviews.
4. Discussion
Interventions for addictive disorders commonly employ both be-
havioral approaches and pharmacotherapy. Evidence-based behavioral
approaches may include motivational interviewing/enhancement,
cognitive behavioral therapy, group approaches, or technology-fa-
cilitated approaches such as telephone quitlines, web-based programs,
and text messaging. Pharmacotherapies for tobacco dependence include
nicotine patch, gum, lozenge, nasal spray, inhaler, as well as varenicline
and buproprion [29]. This study addresses the significant challenge of
deciding how to best treat tobacco dependence in the ED where low
income smokers typically get treated.
It is common to treat behavioral disorders and addictions with
multi-component approaches. Given the complex behavioral, genetic,
physiologic, and environmental factors that mediate disorders such as
addiction, it is perhaps unsurprising that combinations of treatments
often work better than monotherapy. Traditional approaches to assess
efficacy typically involve randomized trials with two or more arms that
test a package of interventions against control, or usual care. An im-
portant shortcoming of this approach is that it does not enable the in-
vestigator to disaggregate the effects of individual interventions or
examine whether important interactions exist between interventions.
This study offers innovation on a number of fronts: (1) this is the
first study to assess the efficacy of the individual components of ED-
initiated tobacco dependence treatment; (2) this is the first ED-based
study to use the MOST clinical trial methodology; (3) this is the first
large study in the ED of mobile health technology for tobacco depen-
dence treatment; (4) the treatment paradigm initiates NRT at the time
of enrollment, without the traditional 2–3 week period prior to a formal
“quit date;” (5) to our knowledge, this is the first MOST trial to add a
qualitative component to the analytic strategy, incorporating qualita-
tive and quantitative assessments of efficacy, cost effectiveness, and
feasibility/acceptability, using a concurrent triangulation mixed
methods approach [60].
Table 2
Components of economic analysis.
Component Health system cost Participant cost State costs
Screening None. Screening information collected for all patients. None. None.
Motivational interview Provider time performing motivational interview (wage × minutes). Average YNHH
wage, conditional on provider training (i.e., MD, nurse practitioner, RA) will be used.
None. No additional time in hospital
due to motivational interview.
None.
Medication (6 weeks) Total price paid by hospital. In sensitivity analysis we will consider average wholesale
price (AWP), since not all providers receive same medication discounts.
None. Assume all costs of medication
borne by provider.
None.
Quitline None. Provider bears no costs for quit line use. Cost of time on QL (avg. wage
rate × min/call).
Marginal cost of QL
user.
Texting None. Texting will be automated. Once developed marginal cost of texting is small. Cost of minutes to participant. None.
Brochure Printing costs of brochure. None. None.
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5. Conclusion
This study is a full-factorial 16-arm trial using the MOST design to
assess the effects of 4 evidence-based therapies in the treatment of to-
bacco dependence among adult smokers visiting a hospital ED. The
therapies are nicotine patches and gum, brief motivational inter-
viewing, telephone-based quitline counseling, and text messaging. The
study uses a mixed methods approach to identify the most efficacious
combination of treatments within a fixed cost constraint. Study end-
points include assessments of clinical efficacy (i.e. biochemically ver-
ified smoking cessation at 3 months), cost effectiveness analysis, and
acceptability of the interventions to study participants. Recruitment of
1056 participants will conclude approximately in February 2019. Once
the optimal combination of interventions is identified, a follow-on
clinical trial will assess its efficacy.
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